NCT04569994View on ClinicalTrials.gov

A Study to Look at the Safety of NNC0363-0845 in Healthy People and People With Type 1 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

September 30, 2020

Primary Completion Date

June 23, 2021

Study Completion Date

June 23, 2021

Conditions
Healthy VolunteersDiabetes Mellitus, Type 1
Interventions
DRUG

NNC0363-0845

A single dose administered s.c. (subcutaneously, under the skin)

DRUG

Placebo (NNC0363-0845)

A single dose administered s.c.

DRUG

Insulin degludec

A single dose administered s.c.

Trial Locations (1)

55116

Novo Nordisk Investigational Site, Mainz

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY